Post Profile






Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders

(European Society for Medical Oncology) The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumors were reported today at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, rese...

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

Health : EurekAlert: Health

(European Society for Medical Oncology) The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first ti...

Thousands of melanoma patients in Europe have no access to new life saving drugs

Health : EurekAlert: Health

(European Society for Medical Oncology) Over 5,000 patients with metastatic melanoma in Europe are denied access to new, life saving drugs every year, according to a survey presented at the ESMO 2016 Congress in Copenhagen.

Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Comments


Copyright © 2016 Regator, LLC